Abstract EZH2 is over-expressed in human colon cancer and is closely associated with tumor proliferation, metastasis and poor prognosis. Targeting and inhibiting EZH2 may be an effective therapeutic strategy for colon cancer. 3-Deazaneplanocin A (DZNep), as an EZH2 inhibitor, can suppress cancer cell growth. However, the anti-cancer role of DZNep in colon cancer cells has been rarely studied. In this study, we demonstrate that DZNep can inhibit the growth and survival of colon cancer HCT116 cells by inducing cellular senescence and apoptosis. The study provides a novel view of anti-cancer mechanisms of DZNep in human colon cancer cells.
Introduction
Colon cancer has become the third leading cause of tumor-related deaths in the world 1 , and its incidence is rapidly rising in Chinese cities along with economic development 2 . Colon cancer normally develops through a multistep process that results from the progressive accumulation of mutations and epigenetic alterations in tumor suppressor genes and oncogenes, which include both DNA hypermethylation and chromatin modifications such as histone methylation and deacetylation 3 . Recently, the study of epigenetic gene silencing by histone methylation has gained attention in the development of colon cancer.
Enhancer of zeste homolog-2 (EZH2), a histone methyltransferase, is the catalytic subunit of polycom repressive complex 2 (PRC2) that methylates H3K27me3 and results in epigenetic control of cancer genes expression 4, 5 . Up-regulation of EZH2 has been found in many malignant human tumors, including colorectal carcinomas, and a high level of EZH2 positively correlates with colon cancer metastasis 6 . Thus, EZH2 has become a promising therapeutic target for colon cancer treatment.
3-Deazaneplanocin A (DZNep), a S-adenosyl-L-homocysteine (AdoHcy) hydrolase, has been shown to be capable of reducing the expression of EZH2 7 . Although DZNep was shown to be able to inhibit the proliferation as well as the metastasis and invasion of a variety of cancer cells, such as lung cancer and breast cancer 8, 9 , little is known with regard to the effects and mechanisms of DZNep on colon cancer cells.
Cellular senescence has become a vital anti-cancer mechanism due to irreversible cell cycle arrest and permanent inhibition of cancer cell growth 10, 11 . Inhibition of EZH2 was shown to promote senescence and apoptosis induced by doxorubicin in gastric cancer cells harboring mutant p53
12
. However, direct evidence linking EZH2 inhibition by pharmacological intervention with cell senescence in colon cancer cells is still lacking. Here, we investigated the role of DZNep in colon cancer HCT116 cells, and found that both senescence and apoptosis contribute to the anti-cancer effects of the compound.
Materials and methods

Reagents and materials
3-Deazaneplanocin A hydrochloride (DZNep) and propidium iodide (PI) were purchased from Sigma-Aldrich. MTT was purchased from Amresco (Solon, OH). AnnexinV-PI was purchased from Beijing 4A Biotech Co., Ltd. Senescence associated β-galactosidase (SA-β-gal) staining kit was purchased from Beyotime Institute of Biotechnology. Antibody for β-actin and EED were purchased from Sigma. EZH2, SUZ12 and other antibodies were purchased from Cell Signaling Technology.
Cell culture
HCT116 was cultured and maintained in DMEM (Hyclone, Logan, UT) supplemented with 10% (v/v) fetal bovine serum (FBS, Life Technology), 100 U/mL penicillin G (Amresco) and 100 μg/mL streptomycin (Amresco). The cells were cultured in a humidified atmosphere of 5% CO 2 at 37 1C.
Cellular viability measurement
Cellular viability was performed with the MTT assay as described previously 7 . The cells were seeded at 5000 cells/well in 96-well 
Colony formation and cell growth assay
Cellular sensitivity to DZNep was determined using a previously described protocol 13 . In brief, HCT116 cells were seeded at a density of 500 cells/well into 35 mm dishes and treated as indicated. After incubation for 2 weeks, the colonies obtained were fixed in 3% paraformaldehyde for 15 min and then washed with PBS followed by staining with hematoxylin. HCT116 cells were seeded into 96-well plate with 10 4 cells/well in triplicate for cell counting at indicated time points with a Countess Cell Counter (Life Technology).
SA-β-gal staining
SA-β-gal activity staining was performed using SA-β-gal staining kit (Beyotime Institute of Biotechnology, Haimen, China) according to the manufacturer's protocol. The cells were seeded at 5 Â 10 4 cells/well in 6-well plates, and treated with DZNep at 5 μmol/L for the indicated time. The cells were washed three times with PBS and fixed with 4% paraformaldehyde for 15 min at room temperature. The cells then were incubated overnight at 37 1C with the working solution containing 0.05 mg/mL X-gal using SA-β-gal staining kit (Beyotime Biotechnology).
Apoptosis assay
Apoptosis assay was performed using the Annexin V Alexa Fluor 488/PI apoptosis detection Kit (Beijing 4A Biotech Co., Ltd.) according to the manufacturer's instructions. Briefly, after treated as indicated, both floating and non-floating cells were collected after trypsinization, and then washed twice in PBS, followed by resuspension in Annexin-V binding buffer at a concentration of 10 6 cells/mL. An aliquot of 100 μL of this suspension was stained with 5 μL of Annexin-V Alexa Fluor 488 and 5 μL PI, and incubated at room temperature in the darkness for 15 min. Subsequently, the cells were added to 400 μL PBS and subjected to FACS analysis in a FACS Calibur (Becton Dickinson instruction, BD Bioscience).
Flow cytometry and cell cycle analysis
The cells were harvested and fixed in 70% ethanol at À20 1C overnight. The fixed cells were stained with PI for 1 h after treatment with RNase at 37 1C for 30 min in the darkness. The stained cells were analyzed for DNA content by FACS. The cell cycle fractions were quantified using the Cell Quest Acquisition and Analysis (BD Bioscience).
Immunoblotting analysis
Immunoblotting analysis was determined using a previously described protocol 14 . (Fig. 1A) . We used 5 μmol/L DZNep at IC 50 range for further study, and found that DZNep significantly inhibited the cellular proliferation in a time-dependent way, as indicated by the growth curve (Fig. 1B) . Longer treatment of DZNep also displayed significant growth inhibition with colony formation assay (Fig. 1C) .
DZNep induces G1 cell cycle arrest in HCT116 cells
We next used flow cytometry to determine whether the suppression of proliferation was due to cell cycle arrest in HCT116 cells. After treatment with DZNep for 24 h, the cellular ratio in G1 phase increased from 41.09% to 55.14%, and the ratio in S phase decreased from 38.24% to 30.73% (Fig. 2 ). Higher ratio of G1 phase was seen upon DZNep treatment for 48 h and 72 h (Fig. 2) . This suggests that DZNep induces G1 cell cycle arrest in HCT116 cells.
DZNep induces cellular senescence in HCT116 cells
Inhibition of EZH2 is suggested to induce cancer cell senescence 15 . We thus checked whether DZNep was able to induce cell senescence in HCT116 cells as well. After the cells were treated with DZNep for 48 h, 72 h and 96 h, we used SA-β-gal staining to observe the senescence-like phenotype, and found that many cells became positively stained upon DZNep exposure (Fig. 3A) . This suggests that DZNep induces cellular senescence simultaneously under these conditions. Similarly, senescence was observed upon EZH2 siRNA treatment for 72 h (Fig. 3B) . 
DZNep regulates cell cycle and senescence related proteins expression in HCT116 cells
We further investigated the possible molecular mechanisms involved. The expression levels of PRC2 proteins (EZH2, EED and SUZ12) were confirmed to be suppressed after treatment with DZNep for 48 h, 72 h, 96 h and 120 h, as shown by immunoblot analysis in HCT116 cells (Fig. 4) . Cell cycle and senescence regulatory proteins were investigated to clarify the underlying mechanism 16 , and a significant increase of p21 and decrease of p-RB protein expression were found upon exposure to the agent. In addition, we examined the expression of p27 and p-CDC2, which are cell cycle regulators as well 17 , and found that DZNep increased p27 and decreased p-CDC2 expression in a timedependent manner (Fig. 4) .
DZNep induces apoptosis in HCT116 cells
We also asked whether apoptosis is involved. Flow cytometry analysis using Annexin V/PI demonstrated that the apoptotic fraction of HCT116 cells was increased in a time-dependent manner following treatment with DZNep (Fig. 5A) . We also analyzed PARP cleavage, a well-known molecular event indicating apoptosis induction 18 , and found a significant increase of PARP cleavage upon treatment with 5 μmol/L DZNep for 24 h, 48 h and 72 h (Fig. 5B) . This indicates that DZNep induces apoptosis as well.
Discussion
EZH2-targeted therapy has become an effective strategy for cancer treatment. For example, blocking the expression of EZH2 by siRNA leads to G1/S cell cycle arrest and growth inhibition in colon cancer 19 . Moreover, decreased EZH2 expression is found to be able to increase the sensitivity to TRAIL-mediated apoptosis in human colon cancer HT29 cells 20 . In the present work, we provide first evidence to show that inhibition of EZH2 by DZNep can directly induce cell senescence, along with apoptosis, in human colon cancer HCT116 cells.
Cellular senescence of HCT116 cells induced by DZNep is demonstrated by G1 phase arrest and an increased number of cells with positive SA-β-gal staining, which is one of most commonly used senescence markers. We found that the cell cycle arrest caused by DZNep can be addressed by the increase of p21 expression and decrease of p-RB expression. Moreover, p27 and p-CDC2, which blocks cell cycle progression at the G1 transition and promotes G1 and G2/M transition 17, 21 , respectively, are found to be separately up-regulated and down-regulated as well. In line with our data, silencing of EZH2 is reported to be linked to the increase of p27 expression in pancreatic cancer cells and HCT116 cells 11, 22 . We also checked the expression of p16, another molecular marker associated with senescence and cell cycle, but did not find any significant change in the protein level (data not shown).
In our work, we also found that DZNep can dose-and timedependently induce colon cancer cell apoptosis, as confirmed by FACS analysis and PARP cleavage (Fig. 5) . Accordingly, DZNepinduced apoptosis has been described in osteosarcoma U2OS and breast cancer MCF7 cells 23, 24 . More importantly, DZNep at a similar dose range was found to induce apoptosis in human colon cancer stem cells as well 25 . Therefore, combined mechanisms are involved in the anti-cancer effects of DZNep on colon cancer. A study by Wu et al. 23 has shown that DZNep induces apoptosis and G1 cell cycle arrest in response to DNA damage in both p53-proficient and p53-deleted HCT116 cells, resulting in induction of FBXO32, a decrease of p21 and an increase of PARP cleavage. This seems to be inconsistent with our data which suggests an increase of p21 upon DZNep exposure. The discrepancy in p21 regulation may rely on the different stresses imposed on the cells.
Taken together, our results demonstrate that DZNep inhibits the growth and survival of colon cancer HCT116 cells by inducing 
